GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sinocelltech Group Ltd (SHSE:688520) » Definitions » Cash Flow from Financing

Sinocelltech Group (SHSE:688520) Cash Flow from Financing : ¥-11 Mil (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Sinocelltech Group Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Mar. 2024, Sinocelltech Group paid ¥0 Mil more to buy back shares than it received from issuing new shares. It received ¥151 Mil from issuing more debt. It paid ¥0 Mil more to buy back preferred shares than it received from issuing preferred shares. It spent ¥28 Mil paying cash dividends to shareholders. It spent ¥128 Mil on other financial activities. In all, Sinocelltech Group spent ¥6 Mil on financial activities for the three months ended in Mar. 2024.


Sinocelltech Group Cash Flow from Financing Historical Data

The historical data trend for Sinocelltech Group's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinocelltech Group Cash Flow from Financing Chart

Sinocelltech Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Financing
Get a 7-Day Free Trial 714.03 1,430.83 445.72 1,597.97 208.50

Sinocelltech Group Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 213.94 -109.69 120.03 -15.77 -5.55

Sinocelltech Group Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Sinocelltech Group's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

Sinocelltech Group's Cash from Financing for the quarter that ended in Mar. 2024 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-11 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sinocelltech Group  (SHSE:688520) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Sinocelltech Group's issuance of stock for the three months ended in Mar. 2024 was ¥0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Sinocelltech Group's repurchase of stock for the three months ended in Mar. 2024 was ¥0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Sinocelltech Group's net issuance of debt for the three months ended in Mar. 2024 was ¥151 Mil. Sinocelltech Group received ¥151 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Sinocelltech Group's net issuance of preferred for the three months ended in Mar. 2024 was ¥0 Mil. Sinocelltech Group paid ¥0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Sinocelltech Group's cash flow for dividends for the three months ended in Mar. 2024 was ¥-28 Mil. Sinocelltech Group spent ¥28 Mil paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Sinocelltech Group's other financing for the three months ended in Mar. 2024 was ¥-128 Mil. Sinocelltech Group spent ¥128 Mil on other financial activities.


Sinocelltech Group Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Sinocelltech Group's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Sinocelltech Group (SHSE:688520) Business Description

Traded in Other Exchanges
N/A
Address
Kechuang Seventh Street, Beijing Economic and Technological Development Zone, Room 307, Building 5, Courtyard 31, Beijing, CHN, 100176
Sinocelltech Group Ltd is engaged in development and industrialization of biopharmaceutical products such as monoclonal antibodies, recombinant proteins and vaccines. The company has developed technology platforms in protein expression vectors, cell line development, serum-free medium development, stoichiometrically controlled fed-batch cell culture, process scale-up, and protein purification. Its capacities include stable CHO cell line development, cell banking and certification, serum-free and protein-free culture medium development, fed-batch cell culture process development, optimization, and process scale-up; protein purification development, and large scale production.
Executives
Xie Liang Zhi Director

Sinocelltech Group (SHSE:688520) Headlines

No Headlines